News

LOCUST WALK NEWS CytoReason secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to scale its AI disease models […]

LOCUST WALK NEWS Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib Ascentage Pharma

LOCUST WALK NEWS Garuda Therapeutics Launches with $72 Million Series A Financing CAMBRIDGE, Mass.–(BUSINESS WIRE)–Garuda Therapeutics, a company creating off-the-shelf,

LOCUST WALK NEWS Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing

LOCUST WALK NEWS eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company

LOCUST WALK NEWS Locust Walk Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on March 1,

LOCUST WALK NEWS Locust Walk Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option PHILADELPHIA

Biotalk Episode 13: 2023 Year-In-Review Report: Global Trends in Biopharma Transactions Click Here for a full summary of the episode. During

Biotalk Episode 12: A Conversation with Soufiane Aboulhouda of Nucleate Click Here for a full summary of the episode. On this

Biotalk Episode 11: A Conversation with Shehnaaz Suliman of ReCode Therapeutics Click Here for a full summary of the episode. On